newsfilter
← Latest News
Business Wire·

LadRx Issues 2024 Update to Shareholders

FDA Acceptance of Arimoclomol Triggers $1 Million Payment LadRx Corporation (OTCQB:LADX) ("LadRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer